Company intelligence / Profile preview

Scienture Holdings

New York, New York, United Statesscientureholdings.com ↗
Ownership
Public · SCNX
Development stage
Commercial
01

Overview

Scienture Holdings is focused on developing, bringing to market, and distributing novel specialty pharmaceutical products and operates a commercialized specialty product (Arbli™, losartan potassium oral suspension) and an integrated web-based pharmacy drug purchasing/trading platform, Trxade[1][4].

Therapeutic areas
Cardiovascular
Modalities
Small moleculePlatform/Service
Industry
Biotech
02

Drug pipeline

1 asset

SCN-107

Unknown
03

Partnerships

Not explicitly stated; references to partnerships with specialty/international manufacturers for the Trxade platform

Beyond the preview

Go deeper on Scienture Holdings.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Scienture Holdings.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call